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Abstract 
Background: Left ventricular (LV) diastolic dysfunction (LVDD) is a well-established and early echocardiographic 
characteristic of diabetic cardiomyopathy. However, there are limited data on the association between impaired fast-
ing glucose (IFG) and LVDD.
Objective: To determine whether IFG is associated with LVDD among middle age adults.
Methods: Amongst 3781 subjects screened in an annual health survey program and referred for an echocardiogram, 
2971 individuals without LV systolic dysfunction or valvular heart disease were selected. Mean age of study popula-
tion was 59 ± 12 years and 75 % were men. The subjects were categorized into three groups: euglycemia (N = 2025), 
IFG (N = 534) and diabetes mellitus (DM; N = 412). Doppler echocardiography readers were blinded to glycemic 
state. Subjects with impaired LV relaxation, pseudo-normal or restrictive filling patterns were defined as having LVDD.
Results: LVDD was diagnosed in 574 (19 %) of subjects and it was more prevalent among patients with IFG and DM 
than in euglycemic individuals (27, 30 and 15 %, respectively; p < 0.001). Patients with IFG and DM had lower ratios of 
early (E) to late (A) trans-mitral flow (0.9 ± 0.3 and 0.9 ± 0.3 vs. 1.1 ± 0.4, respectively, p < 0.001). LV hypertrophy (LVH) 
was also more prevalent among patients with IFG and DM (11 and 18 %, respectively, vs. 9 %; p < 0.001). Multivari-
ate binary logistic regression model adjusted to age, gender, obesity, LVH, renal function, total, high and low density 
lipoprotein cholesterol, triglycerides, ischemic heart disease, hypertension and LV ejection fraction showed that 
patients with IFG were 43 % more likely to have LVDD compared with euglycemic subjects (95 % confidence interval 
1.12–1.83, p = 0.004).
Conclusions: IFG is independently associated with a significant increase in the likelihood for the presence of LVDD in 
middle aged adults.
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Background
Impaired fasting glucose (IFG) is a harbinger of diabetes 
mellitus (DM) [1], a major risk factor for cardiovascular 
morbidity and heart failure (HF) [2]. Early derangements 
in glucose metabolism are related to cardiovascular mor-
bidity [3–5]. Previous studies have suggested that one of 
the earliest structural changes related to DM is left ven-
tricular (LV) diastolic dysfunction (LVDD), preceding the 
emergence of systolic dysfunction and HF [6–9]. Early 
cardiac damage as reflected by cardiac chamber enlarge-
ment, left ventricular hypertrophy (LVH) and LV flow 
changes were shown to be related to impaired glucose 
tolerance (IGT) [10–12]. However a possible association 
between IFG and LVDD is controversial [13, 14]. Thus, 
the aim of the current study was to investigate whether 




The study population comprised subjects who were 
referred for an echocardiographic examination as part of 
an annual medical screening program in a tertiary Medi-
cal Center. Study population was described in previous 
works [15–18], and includes mainly apparently healthy 
men and women who pass annual health screening sur-
vey examinations. Shortly, all participants are inter-
viewed during each annual examination using standard 
questionnaires that gather data regarding demographic 
characteristics, health related habits (e.g. degree of physi-
cal activity) and medical history. An attendant physician 
at the center performs a complete medical interview and 
physical examination, including blood pressure measure-
ment. Thereafter, blood samples are collected after a 12 h 
fast and analyzed immediately. All subjects undergo a 
maximal exercise stress test according to the Bruce pro-
tocol in each check-up. A computerized database of all 
annual visits in this center, since the year 2000 serves as 
the source of data for this study. The institutional review 
board of the Sheba medical center approved this study on 
the basis of strict maintenance of participants’ anonymity 
during database analysis, accordingly no individual con-
sent was obtained.
From 01.02.2004 to 31.01.2014—a total of 22,402 sub-
jects were screened in the annual program and 3871 of 
them were referred for echocardiography at the dis-
cretion of their attending physician. Subjects with sys-
tolic dysfunction (LVEF <50  %) or valvular diseases 
were excluded (N =  376). Additional 508 subjects were 
excluded due to presence of atrial fibrillation or time to 
completion of echocardiography of >1  year. Thus, the 
final study sample comprised 2971 subjects.
Echocardiographic examination and parameters
Two-dimensional transthoracic echocardiographic and 
Doppler studies were obtained with clinical ultrasound 
machines equipped with 3.5  MHz transducers using 
standard views. Since 2004 the studies were digitally 
stored (McKesson’s Horizon Cardiology™ Medical Soft-
ware, Tel-Aviv, Israel). LV systolic function was visually 
estimated by echocardiography specialists. LVDD was 
defined as such by experienced readers in the echocardi-
ographic exam summary and was determined according 
to accepted guidelines at the time of the study perfor-
mance [19, 20], through assessment of cardiac function 
by pulsed-wave Doppler examination of mitral inflow 
and Doppler tissue imaging of the mitral annulus. All 
subjects with impaired LV relaxation, pseudo-normal or 
restrictive filling patterns were defined as having LVDD.
Interventricular diastolic septal thickness (IVSd), LV 
diastolic diameter (LVDd), LV systolic diameter (LVDs) 
and left atrial diameter were determined. Peak velocities 
of early (E) and late (A) trans-mitral flow and decelera-
tion time (DT) were determined, and the ratio E/A was 
calculated. LV mass (LVM) was determined according to 
the formula introduced by Devereux et al. [21] and nor-
malized according to body surface area (BSA) to produce 
LV mass index (LVMI), adjustments of LVM to Ht2.7 were 
also made to correct for the effect of obesity on LVM 
evaluation [22]. LVH was determined separately by each 
correction (BSA and Ht2.7) according to the American 
society of cardiology and European association of echo-
cardiography guidelines. Thus, LVH was defined as LVM/
BSA >95 kg/m2 for women and >115 kg/m2 for men, and 
as LVM/Ht2.7 >44  g/m2.7 for women and >48  g/m2.7 for 
men, for each criteria separately [23].
We also calculated the relative wall thickness (RWT) 
(measured as: twice the posterior wall thickness divided 
by LVDd) and determined the LV anatomical pattern in 
each participant (i.e. normal LV, concentric LV remod-
eling, concentric LVH and eccentric LVH) [24]. Normal 
LVM and RWT were defined as normal LV anatomy, nor-
mal LVM and RWT >0.42 as concentric LV remodeling, 
increased LVM and RWT >0.42 as concentric LVH and 
increased LVM in the presence of RWT <0.32 as eccen-
tric LVH.
Definitions
IFG was defined according to current guidelines [25] 
as a 12  h fasting plasma glucose measurement between 
100 and 125 in subjects without known DM. Blood sam-
ples were drawn before echocardiography (mean time to 
echocardiography: 74 ± 83 days). Diabetes mellitus was 
defined according to past or current diagnosis of DM or 
a fasting plasma glucose level >125 mg/dL or the use of 
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hypoglycemic drugs. The remainder participants were 
defined as euglycemic.
Obesity was defined according to body mass index 
(BMI)—normal <25  kg/m2, overweight >25–30  kg/m2 
and obese >30 kg/m2. Renal function was assessed using 
Cockroft–Gault formula to produce creatinine clearance 
(Crcl). Hypertension was defined as the presence of two 
blood pressure measurements >140/90 mmHg in two dif-
ferent occasions, a past medical diagnosis or treatment 
with anti-hypertensive drugs.
Statistical analysis
Continuous data were compared with student t test and 
one-way ANOVA. Categorical data were compared with 
the use of Chi square test or Fischer exact test. Trend anal-
ysis was done using polynomial one-way-anova test for 
parametric and the Jonckheere–Terpstra test for non-par-
ametric variables. Multivariate binary logistic regression 
modeling was used to evaluate the odds ratio of LVDD 
among subjects according to their glycemic state (euglyce-
mic, IFG and DM). All models were further adjusted for 
the following specified covariates: age, gender, hyperten-
sion, obesity, LVH (determined by LVMI and LVM/Ht2.7), 
ejection fraction (EF), ischemic heart disease (IHD) and 
renal function. Odds ratios (and 95 % confidence intervals 
[CI]) for LVDD in subjects with DM and IFG were com-
pared to euglycemic participants as the reference group.
In a confirmatory sub-analysis, we also divided the 
cohort into tertiles according to LVM and LV anatomi-
cal pattern in each participant (i.e. normal LV, concen-
tric LV remodeling, concentric LVH and eccentric LVH). 
We then replaced the main definition of LVH (according 
to LVMI or LVM/Ht2.7) with these two definitions (i.e. 
LVM tertiles and the LV anatomic patterns) as covariates 
in two separate binary logistic regression models (with 
LVDD as the dependent variable).
Interaction-term analysis was used to evaluate the con-
sistency of the association between IFG and LVDD in 
specified risk subsets categorized by age, gender, creati-
nine clearance, hypertension, BMI, low and high density 
lipoprotein cholesterol levels and LV anatomical features 
(LVH, LVM tertiles and 4 LV anatomical subgroups). In 
this analysis IFG subjects were compared with euglyce-
mics as the reference group, while those with DM were 
excluded. Interactions were tested separately, adjusted 
for all the other relevant covariates.
Statistical significance was accepted for 2-sided 
p  <  0.05. The statistical analyses were performed with 
IBM SPSS version 20.0 (Chicago, IL, USA).
Results
Among 2971 study participants, mean age was 59 ±  12 
and 75  % were men. There were 343 (12  %) active 
smokers and mean BMI was 26.8 ± 4 kg/m2. Hyperten-
sion was diagnosed in 1366 (46  %), mean systolic and 
diastolic blood pressures were 129 ± 18/79 ± 10 mmHg, 
respectively.
Among study subjects, 2025 (68  %) were euglycemic, 
534 (18 %) had IFG, and 412 (14 %) had DM. The clini-
cal and laboratory characteristics of study subjects by the 
three glycemic categories are presented in Table  1. The 
frequency of baseline clinical cardiovascular risk factors, 
including an older age, higher BMI, increased creatinine 
level, hypertension, and the presence of ischemic heart 
disease, was lowest in the euglycemic group and highest 
in the DM group (p  <  0.001 both for the overall differ-
ence among the three groups and for trend, for all param-
eters). Total, low and high density lipoprotein cholesterol 
(LDL-c and HDL-c, respectively) and triglyceride levels 
were all significantly different between groups (p < 0.001, 
for all).
Echocardiographic indices and LVDD
LVDD was diagnosed in 574 (19 %) subjects, 473 (94.8 %) 
of them had grade 1 diastolic dysfunction (impaired 
relaxation, defined by the presence of an E/A ratio <0.8, 
a deceleration time >200  ms and E/E′ relation <8 in 
the presence of an enlarged left atrium), 23 patients a 
pseudo-normal pattern (4.6 %) and 3 a restrictive filling 
pattern (0.6 %). The mean LVEF of the entire population 
was 60 ± 3 %.
Echocardiographic indices of study subjects by the 
three glycemic groups are presented in Table 2. LV dias-
tolic dimension and IVSd were directly correlated with 
the level of dysglycemia (p  <  0.001 for trend, for both). 
LVM, LVMI, LVM/Ht2.7 and left atrium area all signifi-
cantly increased from normal to IFG and DM (p < 0.001 
for the overall difference among the 3 groups and for 
trend for all comparisons). LVH (as adjusted either for 
BSA or Ht2.7) was significantly more prevalent in sub-
jects with IFG and DM compared to those who were 
euglycemic (p < 0.001 for both adjustments). E/A ratios 
were lower in subjects with IFG and DM as compared 
to euglycemics (p  <  0.001). There was a non-significant 
increase in deceleration time among the 3 groups. E/E′ 
(early mitral flow to early mitral annular movement) 
ratio significantly increased with the level of dysglycemia 
(p < 0.001 both for the overall difference among the three 
groups and for trend).
Notably, of 574 participants diagnosed with LVDD, only 
a minority met the criteria for LVH—159 (28 %) according 
to LVMI and 117 (20 %) according to LVM/Ht2.7.
LVDD and glycemic groups
The prevalence of LVDD was significantly higher 
among subjects with both IFG (27 %) and DM (30 %), as 
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compared to euglycemic participants (15  %) (p  <  0.001 
for the overall difference among the three groups, and for 
the comparison between both the IFG and DM groups 
with euglycemic group; Fig. 1).
Univariate binary logistic regression model showed 
that subjects with IFG and DM were significantly more 
likely to have LVDD (OR = 2.01 95 % CI [1.61–2.35] and 
OR = 2.40, 95 % CI [1.88–3.06], respectively; p < 0.001 
for both comparisons). Multivariate binary logistic 
regression analysis showed consistent findings (Table 3) 
After adjustment for age, gender, obesity, creatinine 
clearance, hypertension, IHD, EF, smoking status, total 
cholesterol, triglycerides level, LDL-c, HDL-c and LVH 
(determined by either LVMI or LVM/Ht2.7)—IFG and 
DM were shown to be independently associated with 
a 43 and 38  % increased likelihood for the presence of 
LVDD, respectively (p = 0.004 for IFG and p = 0.03 for 
DM).
Consistent findings were shown when the main defi-
nition of LVH was replaced by LVM tertiles or by the 
presence of an abnormal LV anatomical pattern (i.e. 
concentric LV remodeling, concentric LVH and eccen-
tric LVH) as covariates in the multivariate model. This 
analysis showed that IFG remained independently asso-
ciated to LVDD when the main definition of LVH was 
replaced by LVM tertiles (OR = 1.40 95 % CI [1.09–1.80]; 
p = 0.009) or by LV anatomical pattern (OR = 1.40 95 % 
CI [1.09–1.80]; p = 0.008).
Subgroup analysis was carried out in 10 specified 
risk subsets and is presented in Fig.  2. This analy-
sis showed that the independent association between 
IFG and the likelihood for the presence of LVDD 
was consistent in subjects categorized by age, gen-
der, Crcl, BMI, HDL-c, LDL-c, LVH, LVM tertiles 
and LV anatomy. No interaction between IFG to the 
specified variables was present. However, the associa-
tion between IFG and LVDD was more pronounced 
among lower risk subjects, including those without a 
history of hypertension (adjusted OR =  1.88 95  % CI 
[1.28–2.77]) as compared to those with hypertension 
(adjusted OR =  1.33 95  % CI [0.98–1.82]; p value for 
IFG-by-hypertension interaction  =  0.06), and among 
younger subjects (age <59; adjusted OR = 2.06 95 % CI 
[1.64–3.18]) as compared with older subjects (adjusted 
OR = 1.35 95 % CI [1.01–1.81]; p value for IFG-by-age 
interaction = 0.06).
Discussion
The main finding of the current study is that IFG is inde-
pendently associated with a significant increase in the 
likelihood for the presence of diastolic dysfunction in 
middle aged adults.
Table 1 Baseline clinical characteristics of study population
BMI body mass index, BP blood pressure, CrCl creatinine clearance, DM diabetes mellitus, IFG impaired fasting glucose, HDL-C high density lipoprotein cholesterol, LDL-
C low density lipoprotein cholesterol, Overweight 25 < BMI ≤ 30, Obese BMI >30, T.C. total cholesterol, TG triglycerides
* Trend analysis was done using polynomial one-way-Annova test for parametric and the Jonckheere–Terpstra test for non-parametric variables
a Mean number of days from blood glucose measurement to echocardiography exam
Euglycemia (2025) IFG (534) DM (412) P P for trend*
Age, years 57 ± 12 62 ± 11 65 ± 10 <0.001 <0.001
Gender, male 1410 (70 %) 450 (84 %) 347 (84 %) <0.001 <0.001
Days to echoa 74 ± 83 71 ± 81 74 ± 84 0.63 0.62
Active smokers 237 (12 %) 53 (10 %) 53 (13 %) 0.34 0.91
Physically active 1554 (77 %) 410 (77 %) 303 (74 %) 0.25 0.12
IHD 188 (9 %) 74 (14 %) 110 (27 %) <0.001 <0.001
BMI 26.1 ± 4 27.6 ± 4 28.5 ± 4 <0.001 <0.001
Overweight 860 (43 %) 261 (49 %) 199 (47 %) <0.001 <0.001
Obese 299 (15 %) 129 (24 %) 136 (33 %) <0.001 <0.001
Systolic BP (mmHg) 127 ± 18 134 ± 18 135 ± 17 <0.001 <0.001
Diastolic BP (mmHg) 79 ± 10 81 ± 10 79 ± 10 <0.001 0.03
Hypertensive 769 (38 %) 293 (55 %) 304 (74 %) <0.001 <0.001
Glucose (mg/dL) 88 ± 8 106 ± 6 131 ± 36 <0.001 <0.001
Hemoglobin (g/dL) 14.2 ± 1 14.5 ± 1 14.0 ± 1 <0.001 0.36
CrCl (mL/min) 84 ± 24 84 ± 26 85 ± 27 0.98 0.85
T.C. (mg/dL) 185 ± 33 180 ± 34 159 ± 35 <0.001 <0.001
LDL-C (mg/dL) 113 ± 26 110 ± 26 95 ± 26 <0.001 <0.001
HDL-C (mg/dL) 50 ± 13 47 ± 11 44 ± 11 <0.001 <0.001
TG (mg/dL) 113 ± 58 131 ± 68 144 ± 83 <0.001 <0.001
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P P for 
trend*
LVEF, % 60.4±3 60.5±3 60±3 0.007 0.022
LV sys. Dimension, cm 2.8±0.3 2.8±0.1 3±0.4 0.58 0.45
LV dia. Dimension, cm 4.67±0.4 4.72±0.4 4.74±0.4 0.002 0.001
LV IVS Dimension, cm 1.0±0.2 1.1±0.2 1.1±0.2 <0.001 <0.001
LV mass, g 164±44 177±42 182±42 <0.001 <0.001
LV mass index, g/m2 85±19 88±18 90±19 <0.001 <0.001
LVH by LVMI 263 (13%) 85 (16%) 95 (23%) <0.001 <0.001
LVM/Height2.7, g/m2.7 37±9 39±9 41±9 <0.001 <0.001
LVH by LVM/height2.7 182 (9%) 59 (11%) 95 (18%) <0.001 <0.001
LA area, cm2 19±4 19±4 20±4 <0.001 <0.001
Peak E wave, cm/s 69±17 69±18 71±20 0.35 0.26
Peak A wave, cm/s 67±17 74±18 80±18 <0.001 <0.001
E/A ratio 1.1±0.4 0.9±0.3 0.9±0.3 <0.001 <0.001
Deceleration time, ms 215±53 220±55 221±53 0.28 0.13
E/E' lateral ratio 8±7 9±8 11±15 <0.001 <0.001
LVM _T1 760 (38%) 140 (27%) 81 (20%)
<0.001 <0.001LVM_T2 666 (33%) 167 (32%) 160 (39%)
LVM_T3 584 (29%) 219 (42%) 167 (41%)
Normal LV, % 1223 (65%) 265 (54%) 173 (47%)
<0.001 <0.001LV Remodeling, % 528 (28%) 181(37%) 144 (39%)
Concentric LVH, % 134 (7%) 45 (9%) 51 (14%)
Eccentric LVH, % 6 (0.2%) 0 0
BSA body surface area, E’ mitral annular movement as measures by tissue Doppler, EF ejection fraction, Dia. diastole, IVS inter ventricular septum, LA left atrium, LV left 
ventricle, LVDD left ventricular diastolic dysfunction, LVM_T LV mass tertile, Ms milliseconds, RWT relative wall thickness, Sys. systole
* Trend analysis was done using polynomial one-way-Annova test for parametric and the Jonckheere–Terpstra test for non-parametric variables
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This finding is further substantiated by evidence of 
increased LV diastolic dimensions, increased LVM, 
LVMI, increased LVM/Ht2.7 and increased LA dimen-
sions, among subjects with IFG. Notably, we have also 
shown that the association between IFG and LVDD was 
independent of LV anatomical abnormalities such as con-
centric LV remodeling and LVH, but appeared to be more 
pronounced among normotensive and younger subjects 
in whom LVDD is generally less prevalent.
Prevalence of LVDD
The reported prevalence of diastolic dysfunction in the 
general population ranges from 11.1 to 34.7  % and is 
influenced by a number of factors including the charac-
teristics of the population, the choice of imaging modali-
ties and the criteria applied for diagnosing diastolic 
dysfunction [26]. In the present study, 574 (19 %) patients 
met the criteria for LVDD.
DM and LVDD
The association between DM and cardiovascular morbid-
ity is well documented, both through increased risk for 
the development of coronary artery disease (CAD) and 
to heart failure unassociated to the presence of CAD [2]. 
Diastolic dysfunction precedes progression to overt heart 
failure either with depressed or preserved EF in many 
diabetic subjects [9, 27]. Actually, a recent major pro-
spective study in patients with long standing type 1 DM, 
found a prevalence of 3.7 % of CHF at the end of a 7 years 
follow up. Diastolic HF constituted 85 % of the cases of 
HF [28].
IFG and LVDD
Early derangements in glucose metabolism are related 
to cardiovascular morbidity [3–5]. Elmm et  al. followed 
10,498 patients for a period of 5.2 years. Sixty five percent 
of the 298 patients who died during follow-up had a glu-
cose metabolic disturbance at baseline. Importantly, IFG 
was associated with a hazard ratio of 2.5 for cardiovascu-
lar mortality [29].
Data regarding the association of IFG to LVDD is 
equivocal, for example while Shimabukuro et al. showed 
that IGT but not IFG is related to LVDD, Capaldo et al. 
recently found that both are related to reduced ratios of 
peak velocities of early (E) to late (A) trans-mitral flow 
and to increased LVM [13, 14].
Our work shows, in a large cohort of apparently healthy 
middle age adults that IFG is independently associated 
with LVDD. These results stress the fact that IFG might 
serve as a marker for a possible early cardiac involve-
ment in the dysglycemic process even in the absence of 
other co-morbidities such as hypertension. It should be 
noted that both the European society for diabetes and the 
American diabetes association do not currently recom-
mend routine echocardiographic screening of patients 
with diabetes or IFG [25, 30].
However, subclinical LVDD is recognized as an impor-
tant predictor of heart failure and long-term mortality 
[31]. In contrast to diabetic societies current heart fail-
ure guidelines [32, 33] give special emphasis to the early 
detection of these asymptomatic changes of left ventricle 
function and the identification of its main risk factors.
In the present analysis prevalence of LVDD was simi-
lar in IFG and DM groups. This apparent paradox may be 
explained by the fact that many patients with DM who 
already suffered cardiac complications (like systolic HF, 
valvular disease and atrial fibrillation) were excluded 
from the analysis and those who left might represent a 
relatively healthier subgroup.
Even after multivariate analysis that included obesity, 
hypertension and LVH, IFG remained closely and inde-
pendently related to LVDD. Interaction analysis showed 
Fig. 1 Rate of LVDD among subjects in different glycemic groups 
[308 (15 %) of euglycemic, 142 (27 %) of those with IFG and 124 
(30 %) of diabetic participants]. *p < 0.001 for the comparison 
between both IFG and DM to euglycemic groups
Table 3 Binary logistic regression: effect of  glycemic 
group on the risk for left ventricular diastolic dysfunction
Model is further adjusted to LVEF, IHD, renal function, smoking status, TC, TG, 
LDL-C and HDL-C
CI confidence interval, DM diabetes mellitus, HDL-c high density lipoprotein 
cholesterol, IFG impaired fasting glucose, IHD ischemic heart disease, LDL-c low 
density lipoprotein cholesterol, LVEF left ventricular ejection fraction, LVH left 
ventricular hypertrophy determined by left ventricular mass index (LVH/BSA), OR 
odds ratio, TC total cholesterol, TG triglycerides
OR 95 % CI P value
IFG vs. normal 1.43 1.12–1.83 0.004
DM vs. normal 1.38 1.04–1.83 0.03
Age (for each 1 year) 1.07 1.06–1.09 <0.001
Gender, male 1.15 0.88–1.52 0.30
Hypertension 1.33 1.07–1.66 0.01
LVH 2.05 1.60–2.62 <0.001
BMI >25 1.44 1.12–1.84 0.005
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that association between IFG and LVDD was strongest 
among young normotensive subjects (data presented in 
Fig.  2). This finding reinforces our hypothesis that dys-
glycemia itself may be related to diastolic dysfunction 
independently of other co-morbidities and anatomical 
abnormalities.
Pathogenesis of diastolic dysfunction in dysglycemia 
and possible treatment directions
The mechanisms underlying the relation between dysgly-
cemia and diastolic dysfunction are many, some grouped 
under the term “Diabetic Cardiomyopathy” claimed by 
Rubler et  al. [34]. and currently under rigorous investi-
gation. These mechanisms include—fibrosis and accu-
mulation of advanced glycosylation end products in the 
myocardium, cardiomyocytes lipotoxicity and direct 
effects of insulin on the myocardium and its vasculature, 
including cellular apoptosis, endothelial dysfunction and 
chronic adrenergic stimulation [6, 35]. Other impor-
tant mechanisms included presence of insulin resistance 
[36–38], excessive visceral adipose tissue [39, 40], activ-
ity of circulating dipeptidyl peptidase-4 [41, 42] and fatty 
acid-binding protein-4 [43].
Lifestyle intervention based on dietary management 
and physical activity is a well-established approach to the 
management of various cardiometabolic diseases, includ-
ing diabetes, obesity and metabolic syndrome. Increasing 
evidence reports favorable and specific effects of lifestyle 
interventions on central obesity, insulin-resistance, glu-
cose intolerance and myocardial function [44–46].
Limitations
The main strength of our study is the relatively large 
cohort size under rigorous follow-up. Despite of that 
there are several limitations: First, this is a cross-sec-
tional retrospective study of a selected group with risk of 
residual confounding. This is reinforced by the nature of 
our population, with a low prevalence of obesity, a good 
physical condition (e.g. 76 % were physically active) and 
an early and effective treatment for their hypertension 
Fig. 2 Odds ratios (and 95 % confidence intervals [CI]) for LVDD in IFG as compared with euglycemic subjects and, P values for interaction between 
IFG to specified (e.g. age and hypertension). The vertical line is the reference HR for LVDD in IFG compared to euglycemic subjects (=1.96). LV_
Anatomy anatomical pattern, LVM_T LVM tertiles
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(e.g. reflected by adequate mean blood pressure values, 
see Table  1). Second, the relatively high prevalence of 
hypertension in our study population probably could be 
a result from a referral bias because hypertensive patients 
are commonly referred for echocardiography as part of 
our screening program. Finally, left ventricular function 
was visually estimated, reflecting common clinical prac-
tice [47, 48].
Conclusion and implications
The systematic evaluation of diastolic function by echo-
cardiography as established by the current guidelines 
enables a more accurate identification of cardiac abnor-
malities in at risk patients at an earlier and hopefully 
reversible stage of their disease. Our work shows that 
IFG is associated to LVDD among middle age adults 
independently of numerous factors, including concen-
tric remodeling, LVH and obesity. These findings support 
evaluation of diastolic function in subjects with IFG for 
possible early cardiac involvement in dysglycemic pro-
cess. Future prospective longitudinal studies are required 
to assess long-term prognosis and the reversibility of 
LVDD through life style modification, drug treatment 
and other medical interventions in these patients.
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